U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 91 - 100 of 2579 results

Status:
Investigational
Source:
INN:fosquidone
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Fosquidone (also known as GR63178A), a pentacyclic pyrroloquinone that was developed as an anticancer agent. Fosquidone participated in phase II clinical trial for the treatment of patients with colorectal, renal and non-small cell lung cancer. However, the drug didn’t show significant antitumor activity. The further development of this drug was discontinued.
Status:
Investigational
Source:
INN:propanocaine
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Propanocaine is a benzyl alcohol derivative with local anesthetics activity
Status:
Investigational
Source:
INN:fepitrizol [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

FEPITRIZOL is a hypnotic agent.
Status:
Investigational
Source:
INN:fenalcomine [INN]
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Fenalcomine is a coronary vasodilator, cardiotonic and local anesthetic agent. It was studied in the treatment of angina pectoris.
Status:
Investigational
Source:
JAN:EMITEFUR [JAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Emitefur or BOF-A2 is a fluorinated pyrimidine antimetabolite exerting antineoplastic properties. It is a compound composed of 5-fluorouracil (5-FU) and 3-cyano-2,6-dihydroxypyridine (CNDP), an inhibitor of 5-FU degradation by dihydrouracil dehydrogenase in order to prolong the blood 5-FU level as well as increase selective toxicity to a tumor. Emitefur demonstrated clinical activity in preliminary studies in Japan. Emitefur development for the treatment of solid tumors has been discontinued.
Status:
Investigational
Source:
INN:gallium (68Ga) rofapitide tetraxetan [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:domoxin
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Domoxin is a hydrazine derivative. It is monoamineoxidase inhibitor. Domoxin was developed as antithrombotic agent.
Status:
Investigational
Source:
INN:lutetium (177Lu) rofapitide tetraxetan [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:timcodar [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Timcodar (also known as VX-853) is a benzenepropanamide derivative patented by Vertex Pharmaceuticals Incorporated as an efflux pump inhibitor for the treatment of multi-drug resistant bacterial infection. Timcodar potentiates the activity of ethidium bromide (EtBr), a model efflux substrate, against three clinically significant gram-positive pathogens: Staphylococcus aureus, Enterococcus faecalis, and Streptococcus pneumoniae. Timcodar weakly inhibits M. tuberculosis growth in broth culture but shows a 10-fold increase in the growth inhibition of M. Tuberculosis cultured in host macrophage cells and demonstrated synergy with rifampin, moxifloxacin, and bedaquiline. In a mouse model of tuberculosis lung infection, timcodar reduces the likelihood of a relapse infection and potentiates the efficacies of rifampin and isoniazid. Timcodar in combination with Doxorubicin was studied in phase 1/2 clinical trials in patients with solid tumors, but no results have been published.
Status:
Investigational
Source:
INN:palinavir
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Palinavir (formerly BILA2011BS) is a potent inhibitor of the human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) proteases and was studied for the treatment of HIV infections. However, information about the current development of this drug is not available.